What is the price target for AMLX stock?
18 analysts have analysed AMLX and the average price target is 22.75 USD. This implies a price increase of 31.33% is expected in the next year compared to the current price of 17.32.
AMYLYX PHARMACEUTICALS INC (AMLX) Forecast, Price Target & Analyst Ratings
NASDAQ:AMLX • US03237H1014
Current stock price
17.32 USD
+0.4 (+2.36%)
At close:
17.32 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AMYLYX PHARMACEUTICALS INC (AMLX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.34
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$22.75
Upside
+ 31.33%
From current price of $17.32 to mean target of $22.75, Based on 18 analyst forecasts
Low
$19.19
Median
$20.91
High
$35.70
Price Target Revisions
1 Month
7.33%
3 Months
10.27%
Price Target Summary
18 Wall Street analysts provided a forecast for the next 12 months for AMLX. The average price target is 22.75 USD. This implies a price increase of 31.33% is expected in the next year compared to the current price of 17.32.
The average price target has been revised upward by 10.27% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.67%
AMLX was analyzed by 18 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about AMLX.
In the previous month the buy percentage consensus was at a similar level.
AMLX was analyzed by 18 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-03-19 | Guggenheim | Maintains | Buy -> Buy |
| 2026-03-04 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-03-03 | Stifel | Initiate | Buy |
| 2026-02-20 | B of A Securities | Maintains | Buy -> Buy |
| 2026-02-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-17 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-16 | Baird | Maintains | Outperform -> Outperform |
| 2025-10-03 | B of A Securities | Maintains | Buy -> Buy |
| 2025-09-16 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-09-15 | Guggenheim | Maintains | Buy -> Buy |
| 2025-08-28 | B of A Securities | Maintains | Buy -> Buy |
| 2025-07-10 | Goldman Sachs | Reiterate | Buy |
| 2025-06-24 | Guggenheim | Initiate | Buy |
| 2025-06-17 | Citigroup | Initiate | Buy |
| 2025-05-14 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-05-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-07 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2025-04-07 | Mizuho | Upgrade | Neutral -> Outperform |
| 2025-03-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-18 | Baird | Upgrade | Neutral -> Outperform |
| 2024-11-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-10-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.34
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 19.80%
- Number of Analysts
- 11
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
-6.39%
EPS (3 Months)
-11.32%
Next Earnings Summary
AMLX is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.34 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 22.23M 7,700.00% | 380.786M 1,612.94% | 87.371M -77.06% | -100.00% | 44.601M | 112.71M 152.71% | 283.25M 151.31% | 472.88M 66.95% | 677.91M 43.36% | 858.11M 26.58% | 963.96M 12.34% | ||
| EBITDA YoY % growth | -200.854M -143.06% | 39.89M 119.86% | -162.273M -506.80% | -156.98M 5.86% | -156.301M -2.31% | -159.78M -2.23% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -201.341M -143.49% | 38.802M 119.27% | -163.177M -520.54% | -159.96M 6.06% | -169.715M -10.71% | -160.2M 5.61% | -99.614M 37.82% | 44.577M 144.75% | 206.92M 364.19% | 378.96M 83.14% | 610.48M 61.09% | 671.84M 10.05% | |
| Operating Margin | -905.72% | 10.19% | -186.76% | N/A | N/A | -359.18% | -88.38% | 15.74% | 43.76% | 55.90% | 71.14% | 69.70% | |
| EPS YoY % growth | -3.43 -84.77% | 0.70 120.41% | -2.47 -452.86% | -1.58 37.25% | -1.39 10.43% | -1.42 -2.51% | -0.74 47.68% | 0.72 196.16% | 2.20 207.12% | 3.28 49.35% | 4.48 36.41% | 5.00 11.50% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.34 19.80% | -0.34 25.77% | -0.34 8.23% | -0.43 -42.21% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | -37.056M 1.57% | -37.523M 11.83% | -39.399M -10.64% | -40.608M -12.55% |
| EBIT Q2Q % growth | -40.775M -7.86% | -40.927M 4.50% | -43.15M -19.77% | -46.285M -26.45% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
14.97%
EPS Next 5 Year
27.87%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
AMYLYX PHARMACEUTICALS INC / AMLX Forecast FAQ
When does AMYLYX PHARMACEUTICALS INC (AMLX) report earnings?
AMYLYX PHARMACEUTICALS INC (AMLX) will report earnings on 2026-05-06.
What are the consensus estimates for AMLX stock next earnings?
The consensus EPS estimate for the next earnings of AMYLYX PHARMACEUTICALS INC (AMLX) is -0.34 USD and the consensus revenue estimate is 0 USD.
Can you provide the analyst count for AMYLYX PHARMACEUTICALS INC stock?
The number of analysts covering AMYLYX PHARMACEUTICALS INC (AMLX) is 18.